The role of CHA2DS2-VASc score in evaluating patients with atrial fibrillation undergoing percutaneous coronary intervention

S Parfrey; AW Teh; L Roberts; A Brennan; D Clark; SJ Duffy; AE Ajani; CM Reid; M Freeman

Journal article

The role of CHA2DS2-VASc score in evaluating patients with atrial fibrillation undergoing percutaneous coronary intervention

S Parfrey, AW Teh, L Roberts, A Brennan, D Clark, SJ Duffy, AE Ajani, CM Reid, M Freeman

Coronary Artery Disease | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

DOI: 10.1097/MCA.0000000000000987

Abstract

Objective The aim of the review was to assess whether CHA2DS2-VASc score is predictive of mortality in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI). Background The CHA2DS2-VASc score is validated in predicting stroke risk in atrial fibrillation. The optimum management strategy for these patients undergoing PCI is still debated. Methods The CHA2DS2-VASc score was calculated in consecutive patients with atrial fibrillation undergoing PCI in a large Australian registry between 2007 and 2013. Patients were divided into low (1-2), intermediate (3-4) and high (≥5) groups. Clinical and procedural data, 30-day, 1-year and long-Term outcomes were compared betw..

View full abstract

University of Melbourne Researchers

Andrew Teh Author

David Clark Author

Related Projects (2)

CENTRE OF RESEARCH EXCELLENCE IN CARDIOVASCULAR OUTCOMES IMPROVEMENT

Quality, safety and the effectiveness of providing prevention and treatments to those with cardiovascular disease is the focus of research o..

NOVEL APPROACHES TO THE PREVENTION AND TREATMENT OF CHRONIC HEART DISEASE AND ITS CO-MORBID COMPLICATIONS

Cardiovascular disease (CVD) and its associated additional disorders constitute major public health problems, especially given the rapidly a..

Grants

Awarded by National Health and Medical Research Council (NHMRC) Fellowship

Awarded by NHMRC

Awarded by NHMRC Centre of Research Excellence Grant

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

The MIG acknowledges funding from Abbott, AstraZeneca, Biotronik, Boston Scientific, Bristol-Myers Squibb, Cordis Johnson & Johnson, CSL, Medtronic, MSD, Pfizer, Sanofi-Aventis, Servier, and ScheringPlough. These companies do not have access to data and do not have the right to review manuscripts or abstracts before publication. CMR is supported by a National Health and Medical Research Council (NHMRC) Fellowship (1045862) and the work supported through an NHMRC Program Grant (1092642). SJD is supported by an NHMRC Project Grant (1065462) and an NHMRC Centre of Research Excellence Grant (1111170).